Company Announcements

In March, Qlucore partnered with TATAA Biocenter, which will use Qlucore’s Omics Explorer Software for providing NGS data analysis and for training courses.

Illumina formed a collaboration with Merck Serono to develop a universal NGS-based oncology diagnostic. The assays will be used to detect and measure multiple variants simultaneously to support clinical trials. The deal includes regulatory approvals and commercialization.

Tute Genomics announced that its database of 8.5 billion annotations of genetic variants is now publicly available through Google Genomics. Other datasets hosted on Google Genomics include Illumina Platform Genomes.

Tute Genomics and DNAnexus announced an integrated solution that allows the access of each company’s respective platforms from either company’s cloud environment for genomic data management.

Under a partnership agreement, N-of-One’s Clinical Interpretation service will be available from within Cartagenia’s Bench Lab NGS software platform.

Clontech Laboratories entered into an exclusive agreement with Ludwig Cancer Research for rights to the Smartseq2 method for single-cell RNA-seq.

Horizon Discovery signed an OEM agreement with ArcherDX to provide its Reference Materials as a stand-alone product with ArcherDX’s Archer FusionPlex kits.

Leucine Rich Bio, which provides the Advanced Genome Interpretation Suite, named NextGen Life Sciences as its partner for the Indian market.

PrimaDiag announced a joint promotion agreement with Roche Diagnostics France for the automation of Roche’s NimbleGen SeqCap Enrichment System using its ACSIA NGSCapture Edition for processing 1–48 samples.

Product Introductions

Station X announced in March the utilization of open-access data from the Cancer Genome Atlas through its cloud-based GenePool platform.

In March, Illumina introduced the TruSight HLA, an end-to-end solution that produces a comprehensive view of the HLA region by sequencing 11 HLA genes. It consists of the MiSeq System, TruSight HLA Sequencing Panel, reagents, and software from Conexio Genomics. The Panel generates results based on 65,000 base pairs.

Thermo Fisher Scientific released the CE-IVD Oncomine Solid Tumor Fusion Transcript kit, which enables the detection of rearrangements involving the ALK, ROS-1, RET and NTRK1 genes from as little as 10 ng of RNA.

Pacific Biosciences launched a Certified Service Provider program, a network of validated service organizations, with the initial certification of six companies. The company also added three new informatics partners: DNAnexus, Biosoft Integrators and Computomics.

Exiqon launched NGS services for miRNAs in blood serum and plasma.

< | >